—
C+
C+ The full Closelook — membership. Open the C+ overview

Immunovant Inc (IMVT) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Immunovant Inc

IMVT in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Immunovant is a clinical-stage biotechnology company that develops antibody therapies for autoimmune diseases. Its main candidate blocks the neonatal receptor that recycles antibodies in the body, a mechanism aimed at conditions such as Graves' disease, myasthenia gravis and lupus-related skin disease. It runs no commercial products yet and depends on trial results to advance its pipeline. Based in Durham, North Carolina, it operates as a subsidiary of Roivant Sciences.
Where it sits in the stack
Immunovant carries no seat in Rubin or Halo, our two Closelook indices, so it sits in the healthcare and biotechnology sleeve of our wider universe rather than inside a build-out stack.
Who it is priced against
Closelook's peer group has no entry for Immunovant; the comparison the market draws is with Argenx, which develops therapies through the same neonatal Fc receptor pathway.
Why Closelook tracks it
It carries a Closelook score, but only one module has been scored so far, so the read is still being built; it holds no index seat and no diary quote yet.
What the diary watches
Whether trial results on its antibody candidate shift the chart, which recently sat below its 50-day average but above its 200-day average.

Immunovant Inc (IMVT) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for IMVT, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Immunovant Inc (IMVT)?

Immunovant Inc trades as IMVT on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is IMVT in a Closelook index?

Not currently — Immunovant Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does IMVT trade against its moving averages?

Pullback inside an uptrend stack: Trades -6.5% vs the 50-day and +20.9% vs the 200-day average, 17.1% below the 52-week high and +158.2% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Immunovant Inc do?

Immunovant is a clinical-stage biotechnology company that develops antibody therapies for autoimmune diseases. Its main candidate blocks the neonatal receptor that recycles antibodies in the body, a mechanism aimed at conditions such as Graves' disease, myasthenia gravis and lupus-related skin disease. It runs no commercial products yet and depends on trial results to advance its pipeline. Closelook's peer group has no entry for Immunovant; the comparison the market draws is with Argenx, which develops therapies through the same neonatal Fc receptor pathway.

Where does Immunovant Inc sit in the AI build-out?

Immunovant carries no seat in Rubin or Halo, our two Closelook indices, so it sits in the healthcare and biotechnology sleeve of our wider universe rather than inside a build-out stack. It carries a Closelook score, but only one module has been scored so far, so the read is still being built; it holds no index seat and no diary quote yet.

What does this page show?

A live price chart with SMA overlays and drawing tools for IMVT, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe